London, UK – Monday 04 September, 2023: ADVANZ PHARMA Corp. Limited (“ADVANZ” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital, and rare disease medicines in Europe, is pleased to announce that we have signed an exclusive licensing and supply agreement with GP Pharm for a peptide specialty injectable generic in a rare disease indication for multiple European countries. GP Pharm is a leading vertically integrated organisation specialising in complex peptide developments. This partnership is another confirmatory step in ADVANZ PHARMA’s strategy to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe.
About ADVANZ PHARMA
ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network. ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity.
For more information, please visit our LinkedIn.
About GP Pharm
GP Pharm is a privately-owned pharmaceutical company located in Barcelona and founded in 2000. The company specializes in the development and manufacturing of high-value and complex injectable products including microsphere, lipid nanoparticles and liposome-based sustained-release drug formulations. The main therapeutic areas of our portfolio are Oncology, Urology and Women's Health with both specialty and hospital products. The company presents a vertical integration working on the complete development of medicines from the R+D+i laboratories until reaching the market through the corresponding preclinical and clinical studies and their registration. In addition, GP Pharm develops and manufactures controlled-release drug formulations for third-party companies and has direct market presence in the Spanish market.
For more information, please visit www.gp-pharm.com
For media inquiries, please contact:
Tel: +44 7776 516979